Experts will convene at the third Miami Cancer Institute Summit of Americas on Immunotherapies for Hematologic Malignancies in January 2022 to discuss advances in immunologically and molecular based system therapies, new-targeted diagnostic and therapeutic strategies for lymphoma, myeloma, and leukemia, the role and timing of hematopoietic cell transplantation, and the latest on CAR T-cell therapies.
The University of Texas MD Anderson Cancer Center and AmMax Bio, Inc. announced a worldwide exclusive license agreement and clinical trial agreement to develop and advance AmMax’s AMB-066 monoclonal antibody therapy as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease as well as those with MRD in other solid tumors.
